Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

This systematic review aims to evaluate the use of intrathecal baclofen (ITB) for hereditary spastic paraparesis (HSP) treatment. An extensive search in two electronical databases was performed. We identified articles published between 1990 and 2022 (PubMed, Scopus), and applied the following inclusion criteria: diagnosis of HSP at the time of the intervention, either familial or sporadic; report on the effect of ITB in patients with HSP; test trial via either bolus injections or continuous infusion tests; and ITB pump implantation. A data extraction sheet based on the Cochrane Consumers and Communication Review Group's data extraction template was created and adapted to collect relevant data. A qualitative analysis was performed to present the results in narrative summary fashion. A total of 6 studies met our inclusion criteria. 51 patients with HSP had a pre-implantation ITB trial. The time since the diagnosis until the pump implantation ranged from 5 to 30 years. The initial bolus ranged from 20 to 50 μg and the mean doses used at steady state ranged from 65 to 705 μg. An improvement in spasticity was observed on the modified Ashworth Scale in patients treated with ITB. Although all studies reported a subjective gait improvement, not all found an objective improvement in gait. The most common side effect reported was catheter-related problems. The findings of this review support the use of ITB as an effective and a viable option for the treatment of spasticity in HSP refractory to conservative therapies. Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.

Citation

Luisa Viana Pinto, Isabel Romeiro, Filipa Gouveia, Joana Ramalho, Sara Ribeiro Silva, Maria Inês Táboas Simões, Joana Rodrigues Leal. Intrathecal baclofen for the management of hereditary spastic paraparesis: a systematic review. International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation. 2024 Mar 01;47(1):3-9

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 38251093

View Full Text